<DOC>
	<DOCNO>NCT02349763</DOCNO>
	<brief_summary>Comparison efficacy side effect intravenous oral regimen dexamethasone prophylaxis paclitaxel-associated hypersensitivity reaction primary ovarian , fallopian tube peritoneal cancer patient receive first cycle combination paclitaxel carboplatin .</brief_summary>
	<brief_title>Dexamethasone Regimens Prophylaxis Paclitaxel-associated Hypersensitivity Reaction</brief_title>
	<detailed_description>The consensus statement management ovarian cancer recommend intravenous paclitaxel ( 175 mg/m2 3 hr ) plus intravenous carboplatin ( area curve [ AUC ] 5.0-7.5 mg/ml∙min ) give every 3 week six cycle first-line chemotherapy . A major limitation paclitaxel poor water solubility , lead use polyoxyethylated castor oil vehicle Cremophor® EL diluent result hypersensitivity reaction ( HSRs ) . Initial P-HSRs generally occur within 10 minute start paclitaxel infusion occur first second infusion . Majority patient manifest minor symptom characterize flush rash sometime life-threatening characterized generalize urticaria , angioedema , bronchospasm hypertension fatal may occur . The reaction likely due release histamine vasoactive substance response Cremophor EL . Originally , prophylactic regimen compose use oral corticosteroid administer two dos 12 6 hour prior paclitaxel infusion accompany histamine receptor H1 H2 antagonist administer intravenously 30 minute prior paclitaxel infusion find successfully limit P-HSRs denote `` Conventional oral prophylactic regimen '' . While three-drug prophylactic regimen show effective , inconvenient patient oral corticosteroid must take 12 6 hour chemotherapy administration . If patient forgets take one pretreatment steroid dos , clear whether patient safely treat . This lead experimental prophylactic regimen one dose intravenous dexamethasone accompany H1 H2 antagonists administer 30 minute prior paclitaxel infusion subsequently report equivalent regimen oral dexamethasone denote `` Modified intravenous prophylactic regimen '' . This intravenous regimen result low total steroid dos precludes issue compliance .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient pathologically diagnose primary ovarian fallopian tube peritoneal cancer Patient start first cycle combination paclitaxel carboplatin Rajavithi Hospital February 1 , 2015 July 31 , 2015 Patient age 1870 year Patient ECOG performance status 02 Patient follow laboratory value obtain : Hemoglobin &gt; 10 g/dL , Absolute neutrophil count &gt; 1500 /mm3 , Platelet count &gt; 100,000/mm3 , Serum creatinine &gt; 2.0 mg/dL , Bilirubin &gt; 1.5 x ULN , alkaline phosphatase SGOT &gt; 3 x ULN Patient able give free inform consent agree participate signing consent form Patient able speak understand Thai Patient able complete quality life questionnaire Functional Assessment Cancer Therapy Ovarian Cancer ( FACTO ) Thai version 4.0 personal logbook Patient previously receive paclitaxel carboplatin Patient receive albuminbound paclitaxel Patient allergic reaction taxanes platinum analogue Patient currently treatment systemic corticosteroid receive systemic corticosteroid histamine antagonist last week Patient allergic reaction corticosteroid diphenhydramine ranitidine Patient severe intolerance lactose Patient allergy severe intolerance product contain castor oil e.g . cyclosporine , teniposide , diazepam , propofol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Dexamethasone</keyword>
	<keyword>Hypersensitivity reaction</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>